Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

Total revenue is expected to decline by a mid-single digit percentage for 2025 compared to 2024 as further declines in multiple sclerosis ...